Literature DB >> 2291661

Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives.

O Y Ke1, E C Krug, J J Marr, R L Berens.   

Abstract

The antimalarial compound qinghaosu (artemisinin) was tested in vitro for the ability to inhibit plaque formation by Toxoplasma gondii in fibroblasts. Qinghaosu at 0.4 microgram/ml for 5 days eliminated all plaques and microscopic foci of T. gondii. At 1.3 micrograms/ml for 14 days, qinghaosu completely eliminated T. gondii. Pretreatment of host cells or T. gondii with qinghaosu had no effect on T. gondii growth. There was no apparent toxicity to human fibroblasts in long-term studies. Of the six qinghaosu derivatives tested, dihydroqinghaosu, 1-propyl-ether-qinghaosu, and 1-butyl-ether-qinghaosu were comparable to qinghaosu. Ethyl-ether-qinghaosu (arteether) and sec-butyl-ether-qinghaosu were more effective. Methyl-ether-qinghaosu (artemether) was the most effective, with a potency approximately 10-fold greater than that of qinghaosu.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291661      PMCID: PMC171972          DOI: 10.1128/AAC.34.10.1961

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Plaque assay of Toxoplasma on monolayers of chick embryo fibroblasts.

Authors:  S D CHAPARAS; R W SCHLESINGER
Journal:  Proc Soc Exp Biol Med       Date:  1959-11

2.  In vitro investigations on the action of pyrimethamine against Toxoplasma gondii.

Authors:  M K COOK; L JACOBS
Journal:  J Parasitol       Date:  1958-06       Impact factor: 1.276

3.  In vitro sensitivity of Naegleria fowleri to qinghaosu and dihydroqinghaosu.

Authors:  D W Cooke; G J Lallinger; D T Durack
Journal:  J Parasitol       Date:  1987-04       Impact factor: 1.276

Review 4.  Current concepts. Treatment of infections associated with human immunodeficiency virus.

Authors:  A E Glatt; K Chirgwin; S H Landesman
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

5.  [Chemotherapeutic effect of artesunate in experimental schistosomiasis].

Authors:  W J Le; J Q You; J Y Mei
Journal:  Yao Xue Xue Bao       Date:  1983-08

6.  Isolation of artemisinin (qinghaosu) from Artemisia annua growing in the United States.

Authors:  D L Klayman; A J Lin; N Acton; J P Scovill; J M Hoch; W K Milhous; A D Theoharides; A S Dobek
Journal:  J Nat Prod       Date:  1984 Jul-Aug       Impact factor: 4.050

7.  [Antimalarial effect and toxicity of methyl-dihydro-artemisinine in animals (author's transl)].

Authors:  H M Gu; M Z Liu; B F Lu; J Y Xu; L J Chen; M Y Wang; W K Sun; B Xu; R Y Ji
Journal:  Zhongguo Yao Li Xue Bao       Date:  1981-06

8.  [Antimalarial activities of 25 derivatives of artemisinine against chloroquine-resistant plasmodium berghei (author's transl)].

Authors:  H M Gu; B F Lu; Z X Qu
Journal:  Zhongguo Yao Li Xue Bao       Date:  1980-09

9.  The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro.

Authors:  A N Chawira; D C Warhurst
Journal:  J Trop Med Hyg       Date:  1987-02

Review 10.  Qinghaosu (artemisinin): an antimalarial drug from China.

Authors:  D L Klayman
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

View more
  19 in total

1.  In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin.

Authors:  Lorraine Jones-Brando; John D'Angelo; Gary H Posner; Robert Yolken
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 2.  A review of dihydroartemisinin as another gift from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.

Authors:  Xu-Guang Zhang; Gui-Xin Li; Shu-Shun Zhao; Fu-Liang Xu; Yun-Hai Wang; Wei Wang
Journal:  Parasitol Res       Date:  2014-03-08       Impact factor: 2.289

3.  Evaluation of drug effects on Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR.

Authors:  Qing Zhao; Ming Zhang; Lingxian Hong; Kefu Zhou; Yuguang Lin
Journal:  Parasitol Res       Date:  2010-02-26       Impact factor: 2.289

Review 4.  Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Authors:  Cecilia Shi Ni Loo; Nelson Siu Kei Lam; Deying Yu; Xin-Zhuan Su; Fangli Lu
Journal:  Pharmacol Res       Date:  2016-11-17       Impact factor: 7.658

5.  Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle.

Authors:  John G D'Angelo; Claudia Bordón; Gary H Posner; Robert Yolken; Lorraine Jones-Brando
Journal:  J Antimicrob Chemother       Date:  2008-11-06       Impact factor: 5.790

6.  Susceptibility of Pneumocystis carinii to artemisinin in vitro.

Authors:  S Merali; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.

Authors:  A Rosowsky; J B Hynes; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Activity of bilobalide, a sesquiterpene from Ginkgo biloba, on Pneumocystis carinii.

Authors:  C Atzori; A Bruno; G Chichino; E Bombardelli; M Scaglia; M Ghione
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.

Authors:  E Holfels; J McAuley; D Mack; W K Milhous; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).

Authors:  Marcel Kaiser; Sergio Wittlin; Angela Nehrbass-Stuedli; Yuxiang Dong; Xiaofang Wang; Andrew Hemphill; Hugues Matile; Reto Brun; Jonathan L Vennerstrom
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.